JP2025511854A5 - - Google Patents
Info
- Publication number
- JP2025511854A5 JP2025511854A5 JP2024559398A JP2024559398A JP2025511854A5 JP 2025511854 A5 JP2025511854 A5 JP 2025511854A5 JP 2024559398 A JP2024559398 A JP 2024559398A JP 2024559398 A JP2024559398 A JP 2024559398A JP 2025511854 A5 JP2025511854 A5 JP 2025511854A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- nucleotide sequence
- human subject
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263329081P | 2022-04-08 | 2022-04-08 | |
| US63/329,081 | 2022-04-08 | ||
| US202263401858P | 2022-08-29 | 2022-08-29 | |
| US63/401,858 | 2022-08-29 | ||
| PCT/US2023/065487 WO2023196941A1 (en) | 2022-04-08 | 2023-04-07 | Treatment of a non-alcoholic fatty liver disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025511854A JP2025511854A (ja) | 2025-04-16 |
| JP2025511854A5 true JP2025511854A5 (https=) | 2026-04-09 |
Family
ID=86286479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559398A Pending JP2025511854A (ja) | 2022-04-08 | 2023-04-07 | 非アルコール性脂肪肝疾患の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250283089A1 (https=) |
| EP (1) | EP4504337A1 (https=) |
| JP (1) | JP2025511854A (https=) |
| CN (1) | CN119789859A (https=) |
| CA (1) | CA3247602A1 (https=) |
| WO (1) | WO2023196941A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121969377A (zh) * | 2023-10-06 | 2026-05-01 | 葛兰素史密斯克莱知识产权(第3号)有限公司 | 非酒精性脂肪性肝病的治疗 |
| TW202540424A (zh) * | 2024-02-03 | 2025-10-16 | 大陸商北京福元醫藥股份有限公司 | 用於抑制HSD17B13表達的siRNA、其綴合物和藥物組合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3011946A1 (en) | 2016-03-07 | 2017-09-14 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
| SG11201901841TA (en) | 2016-09-02 | 2019-03-28 | Arrowhead Pharmaceuticals Inc | Targeting ligands |
| TN2020000038A1 (en) * | 2017-09-14 | 2021-10-04 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use |
| KR102769565B1 (ko) | 2018-09-19 | 2025-02-20 | 애로우헤드 파마슈티컬스 인코포레이티드 | 17베타-HSD 유형 13- (HSD17B13)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법 |
| AR121672A1 (es) * | 2020-03-26 | 2022-06-29 | Arrowhead Pharmaceuticals Inc | AGENTES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3, COMPOSICIONES FARMACÉUTICAS DE ESTA, Y MÉTODOS DE USO |
-
2023
- 2023-04-07 WO PCT/US2023/065487 patent/WO2023196941A1/en not_active Ceased
- 2023-04-07 CN CN202380045597.9A patent/CN119789859A/zh active Pending
- 2023-04-07 CA CA3247602A patent/CA3247602A1/en active Pending
- 2023-04-07 EP EP23721243.6A patent/EP4504337A1/en active Pending
- 2023-04-07 JP JP2024559398A patent/JP2025511854A/ja active Pending
- 2023-04-07 US US18/854,700 patent/US20250283089A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7674420B2 (ja) | Ｌｄｈａの発現を阻害するための方法及び組成物 | |
| JP2022501040A5 (https=) | ||
| ES2676146T3 (es) | Composiciones de ARNi de Serpina1 y métodos de uso de las mismas | |
| JP6370860B2 (ja) | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 | |
| JP2021518125A5 (https=) | ||
| JP2025511854A5 (https=) | ||
| JP2019504112A5 (https=) | ||
| ES2743600T3 (es) | Métodos de tratamiento de los trastornos inflamatorios vasculares | |
| JP2019500345A (ja) | 肝臓病の処置のための組成物および方法 | |
| JP2024515423A5 (https=) | ||
| WO2023278802A1 (en) | Formulations for oral delivery of nucleic acids | |
| JP2024516356A5 (https=) | ||
| US20240043847A1 (en) | New therapy | |
| JP2023506258A5 (https=) | ||
| JP2019500334A (ja) | がんの治療において治療薬として使用するための、モノカルボン酸トランスポーター４（ｍｃｔ４）アンチセンスオリゴヌクレオチド（ａｓｏ）阻害剤 | |
| JP2023529903A5 (https=) | ||
| JP2024522996A5 (https=) | ||
| RU2766356C2 (ru) | Кобитолимод для применения при лечении воспалительного заболевания кишечника | |
| JP2025511854A (ja) | 非アルコール性脂肪肝疾患の治療 | |
| Wang et al. | Aptamer-functionalized-nanoflower loading allicin ameliorates obesity through regulating adipose tissue energy expenditure | |
| KR20200110684A (ko) | 궤양성 대장염을 앓고 있는 환자를 치료하기 위한 조성물, 및 약물로서의 조성물의 용도 | |
| TW202434264A (zh) | 降低一級預防受試者中重大不良心血管事件風險之方法 | |
| Gizem et al. | A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020 | |
| JP2024530030A (ja) | 非天然核酸リガンドを有効成分として含む三重陰性乳癌の治療のための薬学的組成物 | |
| HK40115827A (zh) | 用於抑制ldha表达的方法和组合物 |